Erratum: Hydrophobic Core Variations Provide a Structural Framework for Tyrosine Kinase Evolution and Functional Specialization (PLoS Genet (2016) 12:2 (e1005885) DOI: 10.1371/journal.pgen.1005885);Hydrophobic Core Variations Provide a Structural Framework for Tyrosine Kinase Evolution and Functional Specialization

PLoS Genetics

Volumn 12, Issue 2, 2016, Pages

  Mohanty, Smita ^a   Oruganty, Krishnadev ^a   Kwon, Annie ^b   Byrne, Dominic P ^c   Ferries, Samantha ^c   Ruan, Zheng ^b   Hanold, Laura E ^b   Katiyar, Samiksha ^a   Kennedy, Eileen J ^b   Eyers, Patrick A ^c   Kannan, Natarajan ^a,b  

^a University of Georgia   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; AURORA A KINASE; DASATINIB; EPHRIN RECEPTOR KINASE A3; GLUTAMIC ACID; HISTIDINE; PHENYLALANINE; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; SERINE; UNCLASSIFIED DRUG; EPHA3 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; EVOLUTION; GENE MUTATION; HUMAN; HYDROGEN BOND; HYDROPHOBICITY; IN VITRO STUDY; MOLECULAR DYNAMICS; MUTATIONAL ANALYSIS; PHYLOGENY; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIMULATION; THERMOSTABILITY; AMINO ACID SEQUENCE; ANTAGONISTS AND INHIBITORS; CHEMICAL PHENOMENA; CHEMISTRY; CONSERVED SEQUENCE; ENZYME ACTIVE SITE; GENETICS; METABOLISM; MOLECULAR EVOLUTION; MOLECULAR GENETICS; MUTATION; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; AURORA KINASE A; CATALYTIC DOMAIN; CONSERVED SEQUENCE; EVOLUTION, MOLECULAR; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MOLECULAR DYNAMICS SIMULATION; MOLECULAR SEQUENCE DATA; MUTATION; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; RECEPTOR PROTEIN-TYROSINE KINASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84959923443     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/JOURNAL.PGEN.1006265     Document Type: Erratum

References (76)

1. Hanks SK, Quinn AM, Hunter T, (1988) The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science241: 42–52. 3291115
2. Hanks SK, Hunter T, (1995) Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J9: 576–596. 7768349
3. Manning G, Plowman GD, Hunter T, Sudarsanam S, (2002) Evolution of protein kinase signaling from yeast to man. Trends Biochem Sci27: 514–520. 12368087
4. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S, (2002) The protein kinase complement of the human genome. Science298: 1912–1934. 12471243
5. Lemmon MA, Schlessinger J, (2010) Cell signaling by receptor tyrosine kinases. Cell141: 1117–1134. doi: 10.1016/j.cell.2010.06.01120602996
6. Robinson DR, Wu YM, Lin SF, (2000) The protein tyrosine kinase family of the human genome. Oncogene19: 5548–5557. 11114734
7. Miller WT, (2012) Tyrosine kinase signaling and the emergence of multicellularity. Biochim Biophys Acta1823: 1053–1057. doi: 10.1016/j.bbamcr.2012.03.00922480439
8. Schultheiss KP, Craddock BP, Tong M, Seeliger M, Miller WT, (2013) Metazoan-like signaling in a unicellular receptor tyrosine kinase. BMC biochemistry14: 4. doi: 10.1186/1471-2091-14-423398683
9. King N, Carroll SB, (2001) A receptor tyrosine kinase from choanoflagellates: molecular insights into early animal evolution. Proc Natl Acad Sci U S A98: 15032–15037. 11752452
10. King N, Westbrook MJ, Young SL, Kuo A, Abedin M, et al. (2008) The genome of the choanoflagellate Monosiga brevicollis and the origin of metazoans. Nature451: 783–788. doi: 10.1038/nature0661718273011
11. Manning G, Young SL, Miller WT, Zhai Y, (2008) The protist, Monosiga brevicollis, has a tyrosine kinase signaling network more elaborate and diverse than found in any known metazoan. Proc Natl Acad Sci U S A105: 9674–9679. doi: 10.1073/pnas.080131410518621719
12. Pincus D, Letunic I, Bork P, Lim WA, (2008) Evolution of the phospho-tyrosine signaling machinery in premetazoan lineages. Proc Natl Acad Sci U S A105: 9680–9684. doi: 10.1073/pnas.080316110518599463
13. Lim WA, Pawson T, (2010) Phosphotyrosine signaling: evolving a new cellular communication system. Cell142: 661–667. doi: 10.1016/j.cell.2010.08.02320813250
14. Liu BA, Shah E, Jablonowski K, Stergachis A, Engelmann B, et al. (2011) The SH2 domain-containing proteins in 21 species establish the provenance and scope of phosphotyrosine signaling in eukaryotes. Sci Signal4: ra83. doi: 10.1126/scisignal.200210522155787
15. Schlessinger J, Lemmon MA, (2003) SH2 and PTB domains in tyrosine kinase signaling. Sci STKE2003: RE12. 12865499
16. Li W, Young SL, King N, Miller WT, (2008) Signaling properties of a non-metazoan Src kinase and the evolutionary history of Src negative regulation. J Biol Chem283: 15491–15501. doi: 10.1074/jbc.M80000220018390552
17. Benner SA, G D, . (1991) Patterns of divergence in homologous proteins as indicators of secondary and tertiary structure: a prediction of the structure of the catalytic domain of protein kinases. Adv Enzyme Regul31: 121–181. 1877385
18. Taylor SS, Radzio-Andzelm E, Hunter T, (1995) How do protein kinases discriminate between serine/threonine and tyrosine? Structural insights from the insulin receptor protein-tyrosine kinase. FASEB J9: 1255–1266. 7557015
19. Hubbard SR, (1997) Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J16: 5572–5581. 9312016
20. Hubbard SR, Wei L, Ellis L, Hendrickson WA, (1994) Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature372: 746–754. 7997262
21. al-Obeidi FA, Wu JJ, Lam KS, (1998) Protein tyrosine kinases: structure, substrate specificity, and drug discovery. Biopolymers47: 197–223. 9817025
22. Bose R, Holbert MA, Pickin KA, Cole PA, (2006) Protein tyrosine kinase-substrate interactions. Curr Opin Struct Biol16: 668–675. 17085043
23. Knighton DR, Cadena DL, Zheng J, Ten Eyck LF, Taylor SS, et al. (1993) Structural features that specify tyrosine kinase activity deduced from homology modeling of the epidermal growth factor receptor. Proc Natl Acad Sci U S A90: 5001–5005. 8389462
24. Ubersax JA, Ferrell JE, Jr. (2007) Mechanisms of specificity in protein phosphorylation. Nat Rev Mol Cell Biol8: 530–541. 17585314
25. Kannan N, Neuwald AF, (2005) Did protein kinase regulatory mechanisms evolve through elaboration of a simple structural component?J Mol Biol351: 956–972. 16051269
26. Kannan N, Taylor SS, Zhai Y, Venter JC, Manning G, (2007) Structural and functional diversity of the microbial kinome. PLoS Biol5: e17. 17355172
27. Oruganty K, Kannan N, (2012) Design principles underpinning the regulatory diversity of protein kinases. Philos Trans R Soc Lond B Biol Sci367: 2529–2539. doi: 10.1098/rstb.2012.001522889905
28. Oruganty K, Kannan N, (2013) Evolutionary variation and adaptation in a conserved protein kinase allosteric network: implications for inhibitor design. Biochim Biophys Acta1834: 1322–1329. doi: 10.1016/j.bbapap.2013.02.04023499783
29. Scheeff ED, Bourne PE, (2005) Structural evolution of the protein kinase-like superfamily. PLoS Comput Biol1: e49. 16244704
30. Kornev AP, Taylor SS, (2010) Defining the conserved internal architecture of a protein kinase. Biochimica et biophysica acta1804: 440–444. doi: 10.1016/j.bbapap.2009.10.01719879387
31. Kornev AP, Taylor SS, Ten Eyck LF, (2008) A helix scaffold for the assembly of active protein kinases. Proc Natl Acad Sci U S A105: 14377–14382. doi: 10.1073/pnas.080798810518787129
32. Taylor SS, Kornev AP, (2011) Protein kinases: evolution of dynamic regulatory proteins. Trends Biochem Sci36: 65–77. doi: 10.1016/j.tibs.2010.09.00620971646
33. Oruganty K, Talathi NS, Wood ZA, Kannan N, (2013) Identification of a hidden strain switch provides clues to an ancient structural mechanism in protein kinases. Proc Natl Acad Sci U S A110: 924–929. doi: 10.1073/pnas.120710411023277537
34. Meharena HS, Chang P, Keshwani MM, Oruganty K, Nene AK, et al. (2013) Deciphering the structural basis of eukaryotic protein kinase regulation. PLoS Biol11: e1001680. doi: 10.1371/journal.pbio.100168024143133
35. Johnson LN, Lowe ED, Noble ME, Owen DJ, (1998) The Eleventh Datta Lecture. The structural basis for substrate recognition and control by protein kinases. FEBS Lett430: 1–11. 9678585
36. Lisabeth EM, Fernandez C, Pasquale EB, (2012) Cancer somatic mutations disrupt functions of the EphA3 receptor tyrosine kinase through multiple mechanisms. Biochemistry51: 1464–1475. doi: 10.1021/bi201407922242939
37. Vearing C, Lee FT, Wimmer-Kleikamp S, Spirkoska V, To C, et al. (2005) Concurrent binding of anti-EphA3 antibody and ephrin-A5 amplifies EphA3 signaling and downstream responses: potential as EphA3-specific tumor-targeting reagents. Cancer Res65: 6745–6754. 16061656
38. Nikolov DB, Xu K, Himanen JP, (2013) Eph/ephrin recognition and the role of Eph/ephrin clusters in signaling initiation. Biochim Biophys Acta1834: 2160–2165. doi: 10.1016/j.bbapap.2013.04.02023628727
39. Day B, To C, Himanen JP, Smith FM, Nikolov DB, et al. (2005) Three distinct molecular surfaces in ephrin-A5 are essential for a functional interaction with EphA3. J Biol Chem280: 26526–26532. 15901737
40. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, et al. (2011) Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol29: 1046–1051. doi: 10.1038/nbt.199022037378
41. O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, et al. (2009) AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell16: 401–412. doi: 10.1016/j.ccr.2009.09.02819878872
42. Scutt PJ, Chu ML, Sloane DA, Cherry M, Bignell CR, et al. (2009) Discovery and exploitation of inhibitor-resistant aurora and polo kinase mutants for the analysis of mitotic networks. J Biol Chem284: 15880–15893. doi: 10.1074/jbc.M109.00569419359241
43. Sloane DA, Trikic MZ, Chu ML, Lamers MB, Mason CS, et al. (2010) Drug-resistant aurora A mutants for cellular target validation of the small molecule kinase inhibitors MLN8054 and MLN8237. ACS Chem Biol5: 563–576. doi: 10.1021/cb100053q20426425
44. Tokarski JS, Newitt JA, Chang CY, Cheng JD, Wittekind M, et al. (2006) The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res66: 5790–5797. 16740718
45. Nagar B, Hantschel O, Young MA, Scheffzek K, Veach D, et al. (2003) Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell112: 859–871. 12654251
46. Sicheri F, Moarefi I, Kuriyan J, (1997) Crystal structure of the Src family tyrosine kinase Hck. Nature385: 602–609. 9024658
47. Skora L, Mestan J, Fabbro D, Jahnke W, Grzesiek S, (2013) NMR reveals the allosteric opening and closing of Abelson tyrosine kinase by ATP-site and myristoyl pocket inhibitors. Proc Natl Acad Sci U S A110: E4437–4445. doi: 10.1073/pnas.131471211024191057
48. Zhang J, Adrian FJ, Jahnke W, Cowan-Jacob SW, Li AG, et al. (2010) Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature463: 501–506. doi: 10.1038/nature0867520072125
49. Jahnke W, Grotzfeld RM, Pelle X, Strauss A, Fendrich G, et al. (2010) Binding or bending: distinction of allosteric Abl kinase agonists from antagonists by an NMR-based conformational assay. J Am Chem Soc132: 7043–7048. doi: 10.1021/ja101837n20450175
50. Halabi N, Rivoire O, Leibler S, Ranganathan R, (2009) Protein sectors: evolutionary units of three-dimensional structure. Cell138: 774–786. doi: 10.1016/j.cell.2009.07.03819703402
51. McLaughlin RN, Jr.Poelwijk FJ, Raman A, Gosal WS, Ranganathan R, (2012) The spatial architecture of protein function and adaptation. Nature491: 138–142. doi: 10.1038/nature1150023041932
52. Bosc N, W B., Aci-Sèche S., Meyer C., Bonnet P, . (2015) A Proteometric Analysis of Human Kinome: Insight into Discriminant Conformation-Dependent Residues. ACS Chem Biol.
53. Liu Y, Gray NS, (2006) Rational design of inhibitors that bind to inactive kinase conformations. Nature Chemical Biology2: 358–364. 16783341
54. del Sol A, Tsai CJ, Ma B, Nussinov R, (2009) The origin of allosteric functional modulation: multiple pre-existing pathways. Structure17: 1042–1050. doi: 10.1016/j.str.2009.06.00819679084
55. Dellus-Gur E, Toth-Petroczy A, Elias M, Tawfik DS, (2013) What makes a protein fold amenable to functional innovation? Fold polarity and stability trade-offs. J Mol Biol425: 2609–2621. doi: 10.1016/j.jmb.2013.03.03323542341
56. Gunasekaran K, Ma B, Nussinov R, (2004) Is allostery an intrinsic property of all dynamic proteins?Proteins57: 433–443. 15382234
57. Meinhardt S, Manley MW, Jr.Parente DJ, Swint-Kruse L, (2013) Rheostats and toggle switches for modulating protein function. PloS one8: e83502. doi: 10.1371/journal.pone.008350224386217
58. Salverda ML, Dellus E, Gorter FA, Debets AJ, van der Oost J, et al. (2011) Initial mutations direct alternative pathways of protein evolution. PLoS Genet7: e1001321. doi: 10.1371/journal.pgen.100132121408208
59. Soskine M, Tawfik DS, (2010) Mutational effects and the evolution of new protein functions. Nat Rev Genet11: 572–582. doi: 10.1038/nrg280820634811
60. Lee DC, Zheng J, She YM, Jia Z, (2008) Structure of Escherichia coli tyrosine kinase Etk reveals a novel activation mechanism. EMBO J27: 1758–1766. doi: 10.1038/emboj.2008.9718497741
61. Chao JD, Wong D, Av-Gay Y, (2014) Microbial protein-tyrosine kinases. J Biol Chem289: 9463–9472. doi: 10.1074/jbc.R113.52001524554699
62. Grangeasse C, Nessler S, Mijakovic I, (2012) Bacterial tyrosine kinases: evolution, biological function and structural insights. Philos Trans R Soc Lond B Biol Sci367: 2640–2655. doi: 10.1098/rstb.2011.042422889913
63. Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, et al. (2003) Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood102: 276–283. 12623848
64. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, et al. (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell2: 117–125. 12204532
65. Agafonov RV, Wilson C, Otten R, Buosi V, Kern D, (2014) Energetic dissection of Gleevec's selectivity toward human tyrosine kinases. Nat Struct Mol Biol21: 848–853. doi: 10.1038/nsmb.289125218445
66. Wilson C, Agafonov RV, Hoemberger M, Kutter S, Zorba A, et al. (2015) Using ancient protein kinases to unravel a modern cancer drug's mechanism. Science347: 882–886. doi: 10.1126/science.aaa182325700521
67. Talevich E, Mirza A, Kannan N, (2011) Structural and evolutionary divergence of eukaryotic protein kinases in Apicomplexa. BMC Evol Biol11: 321. doi: 10.1186/1471-2148-11-32122047078
68. Neuwald AF, (2009) Rapid detection, classification and accurate alignment of up to a million or more related protein sequences. Bioinformatics25: 1869–1875. doi: 10.1093/bioinformatics/btp34219505947
69. Neuwald AF, (2014) Evaluating, comparing, and interpreting protein domain hierarchies. J Comput Biol21: 287–302. doi: 10.1089/cmb.2013.009824559108
70. Boutet E, Lieberherr D, Tognolli M, Schneider M, Bairoch A, (2007) UniProtKB/Swiss-Prot. Methods Mol Biol406: 89–112. 18287689
71. Crooks GE, Hon G, Chandonia JM, Brenner SE, (2004) WebLogo: a sequence logo generator. Genome Res14: 1188–1190. 15173120
72. Lindorff-Larsen K, Piana S, Palmo K, Maragakis P, Klepeis JL, et al. (2010) Improved side-chain torsion potentials for the Amber ff99SB protein force field. Proteins78: 1950–1958. doi: 10.1002/prot.2271120408171
73. Fiser A, Sali A, (2003) ModLoop: automated modeling of loops in protein structures. Bioinformatics19: 2500–2501. 14668246
74. Davis TL, Walker JR, Allali-Hassani A, Parker SA, Turk BE, et al. (2009) Structural recognition of an optimized substrate for the ephrin family of receptor tyrosine kinases. FEBS J276: 4395–4404. doi: 10.1111/j.1742-4658.2009.07147.x19678838
75. Vedadi M, Niesen FH, Allali-Hassani A, Fedorov OY, Finerty PJ, Jr.et al. (2006) Chemical screening methods to identify ligands that promote protein stability, protein crystallization, and structure determination. Proc Natl Acad Sci U S A103: 15835–15840. 17035505
76. Shi G, Yue G, Zhou R, (2010) EphA3 functions are regulated by collaborating phosphotyrosine residues. Cell Res20: 1263–1275. doi: 10.1038/cr.2010.11520697431